Cancer
Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers an...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Livre numérique |
| Idioma: | Anglais |
| Publicat: |
Berlin, Heidelberg :
Springer Berlin Heidelberg
[20..].
Cham : Springer Nature |
| Edició: | 1st ed. 2007. |
| Col·lecció: | Topics in Medicinal Chemistry
1 |
| Accés en línia: | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex Accès Université d'Orléans Accès INSA CVL |
| Nota: |
Archives Springer e-books (Licence nationale) Archives Springer e-books (Licence nationale) |
| Autres localisations: | Voir dans le Sudoc |
| Variante du titre: | With contributions by numerous experts |
| Edition sous un autre format: | • Cancer, Texte imprimé, 9783540331193 • Cancer, Texte imprimé, 9783540822011 • Cancer, Texte imprimé, 9783642069666 • Cancer, Texte imprimé, 9783540331193 |
| LEADER | 04275nam a22003857a 4500 | ||
|---|---|---|---|
| 001 | 938529 | ||
| 008 | 080410q2000 xx ||| |||| 00| 0 eng d | ||
| 009 | PPN123132878 | ||
| 020 | |a 9783540331209 | ||
| 041 | 0 | |a eng | |
| 082 | |a 615.19 | ||
| 100 | 1 | |a Bradbury, Robert H. | |
| 240 | 1 | 0 | |a With contributions by numerous experts |
| 245 | 1 | 0 | |a Cancer |c edited by Robert H. Bradbury. |
| 250 | |a 1st ed. 2007. | ||
| 260 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg. | ||
| 260 | |a Cham : |b Springer Nature, |c [20..]. | ||
| 490 | 0 | |a Topics in Medicinal Chemistry |v 1 |x 1862-247X | |
| 500 | |a Archives Springer e-books (Licence nationale) | ||
| 500 | |a Archives Springer e-books (Licence nationale) | ||
| 505 | 1 | |a Overview Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic Survival Signaling Progress in the Development of Agents to Control the Cell Cycle HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy Bcr-Abl Kinase Inhibitors | |
| 506 | |a Accès en ligne pour les établissements français bénéficiaires des licences nationales | ||
| 506 | |a Accès soumis à abonnement pour tout autre établissement | ||
| 506 | |a Conditions particulières de réutilisation pour les bénéficiaires des licences nationales. https://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 | ||
| 520 | |a Thephosphatidylinositol-3-kinase/proteinkinase(PI3K/PKB)signalingpa- way also known as the survival or anti-apoptotic pathway plays an - portant role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in - man cancers and its potential biological effects (e. g. , competitive growth advantage, evasion from apoptosis and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents. Following this strategy, a number of compounds have demonstrated antitumor activity in preclinical and clinical settings by targeting directly or indirectly the different components of this pathway. This work covers - cent salient medicinal chemistry achievements in the identi?cation of these pathway modulators, updating recent reports on this class of potential c- cer drugs [1 4]. To help the reader, each section of this piece of work starts with a brief background to understand the target rationale and then moves on to the lead discovery, drug optimization, and clinical results stages as - propriate. A schematic representation of signaling through this pathway and the pathway components covered herein are shown in Fig. 1. Fig. 1 Schematic representation of signaling through the PI3K/PKB pathway 172 C. Garcia-Echeverria 2 Insulin-likeGrowthFactorI Receptor The Insulin-like Growth Factor-I Receptor (IGF-IR) is a member of the - sulin receptor family of tyrosinekinases. This transmembrane-spanning p- tein is composed of two ?-andtwo ?-subunits linked by disul?de bonds | ||
| 700 | 1 | |a Bradbury, Robert H. |4 edt | |
| 776 | 0 | |t Cancer |b Texte imprimé |z 9783540331193 | |
| 776 | 0 | |t Cancer |b Texte imprimé |z 9783540822011 | |
| 776 | 0 | |t Cancer |b Texte imprimé |z 9783642069666 | |
| 776 | 0 | |t Cancer |b Texte imprimé |z 9783540331193 | |
| 856 | 4 | |q PDF |u https://doi.org/10.1007/978-3-540-33120-9 |z Accès sur la plateforme de l'éditeur | |
| 856 | 4 | |u https://revue-sommaire.istex.fr/ark:/67375/8Q1-8D1K08BV-W |z Accès sur la plateforme Istex | |
| 856 | 4 | |5 452349901:74789826X |u https://ezproxy.univ-orleans.fr/login?url=https://dx.doi.org/10.1007/978-3-540-33120-9 |z Accès Université d'Orléans | |
| 856 | 4 | |5 180339901:750911239 |u https://ezproxy.insa-cvl.fr/login?qurl=https://dx.doi.org/10.1007/978-3-540-33120-9 |z Accès INSA CVL | |
| 997 | |0 938529 |1 Livre numérique |a Ressource numérique |b INSA |b ENSA |c 0/Bibliothèque numérique/ |c 1/Bibliothèque numérique/Autre ressource numérique/ | ||